| Literature DB >> 29183316 |
Maren van Son1, Nina Hårdnes Tremoen2,3, Ann Helen Gaustad4,2, Frøydis Deinboll Myromslien2, Dag Inge Våge3, Else-Berit Stenseth2, Teklu Tewoldebrhan Zeremichael2, Eli Grindflek4.
Abstract
BACKGROUND: Sperm DNA is protected against fragmentation by a high degree of chromatin packaging. It has been demonstrated that proper chromatin packaging is important for boar fertility outcome. However, little is known about the molecular mechanisms underlying differences in sperm DNA fragmentation. Knowledge of sequence variation influencing this sperm parameter could be beneficial in selecting the best artificial insemination (AI) boars for commercial production. The aim of this study was to identify genes differentially expressed in testis tissue of Norwegian Landrace and Duroc boars, with high and low sperm DNA fragmentation index (DFI), using transcriptome sequencing.Entities:
Keywords: Differential expression; Sperm DNA integrity; Transcriptome profiling
Mesh:
Year: 2017 PMID: 29183316 PMCID: PMC5706377 DOI: 10.1186/s12917-017-1279-x
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
DFI measurements for the different boars used in this study
| Group | Boar | n(ejaculates) | DFI mean | DFI SD |
|---|---|---|---|---|
| Landrace low | L1 | 2 | 0.62% | 0.10% |
| L2 | 1 | 0.73% | ||
| L3 | 1 | 0.82% | ||
| L4 | 3 | 1.50% | 0.33% | |
| L5 | 4 | 1.52% | 0.68% | |
| Landrace high | L6 | 1 | 6.41% | |
| L7 | 2 | 5.47% | 1.69% | |
| L8 | 6 | 7.26% | 5.11% | |
| L9 | 7 | 8.07% | 3.85% | |
| Duroc low | D1 | 1 | 1.05% | |
| D2 | 2 | 1.07% | 0.37% | |
| D3 | 2 | 1.08% | 0.34% | |
| D4 | 1 | 1.11% | ||
| D5 | 3 | 1.13% | 0.35% | |
| Duroc high | D6 | 1 | 4.13% | |
| D7 | 1 | 4.77% | ||
| D8 | 1 | 4.14% | ||
| D9 | 1 | 4.69% | ||
| D10 | 1 | 5.63% | ||
| D11 | 3 | 5.36% | 3.64% |
The number of ejaculates and mean DFI value with SD is presented for each boar
Differentially expressed genes common for the two breeds Landrace and Duroc
| Gene symbol | Gene name | FDR L | FDR D |
|---|---|---|---|
| ACER2 | alkaline ceramidase 2 | 1.61E-02 | 3.74E-02 |
| ACTN4 | alpha-actinin | 1.52E-02 | 1.34E-02 |
| APP | amyloid beta A4 protein | 2.73E-02 | 1.34E-02 |
| ATG4A | autophagy related 4A, cysteine peptidase | 4.02E-03 | 2.13E-02 |
| BGN | Biglycan | 2.64E-02 | 1.88E-02 |
| BMP1 | bone morphogenetic protein 1 | 4.60E-02 | 1.09E-02 |
| SERPING1 | Serpin family G member 1 | 2.68E-02 | 1.89E-02 |
| GLMP | Glycosylated lysosomal membrane protein | 3.66E-03 | 3.59E-02 |
| C1R | complement component 1, r subcomponent | 4.29E-02 | 2.13E-02 |
| C4A |
| 2.86E-02 | 1.84E-03 |
| CA4 | carbonic anhydrase IV | 4.06E-02 | 1.44E-02 |
| CAT | Catalase | 1.01E-02 | 1.24E-02 |
| CDC42EP1 | CDC42 effector protein (Rho GTPase binding) 1 | 4.93E-02 | 2.42E-02 |
| CITED1 | Sus scrofa Cbp/p300-interacting transactivator | 2.31E-02 | 1.11E-02 |
| ENSSSCG00000001711 | Uncharacterized protein | 3.89E-02 | 2.72E-02 |
| COL3A1 | collagen, type III, alpha 1 | 4.40E-02 | 3.59E-02 |
| COPZ2 | coatomer protein complex, subunit zeta 2 | 1.04E-02 | 4.75E-02 |
| CPED1 | cadherin-like and PC-esterase domain containing 1 | 4.51E-03 | 2.72E-02 |
| CSF1R | colony stimulating factor 1 receptor | 3.86E-02 | 2.92E-02 |
| CTDSPL | CTD small phosphatase-like | 1.52E-02 | 1.66E-02 |
| CTSA | cathepsin A | 2.43E-02 | 2.71E-02 |
| CTSB | Sus scrofa cathepsin B (CTSB) | 1.26E-02 | 9.65E-03 |
| CTSH | Sus scrofa cathepsin H (CTSH), mRNA | 2.07E-02 | 3.84E-02 |
| CYP11A1 | Sus scrofa cytochrome P450, family 11, subfamily A, polypeptide 1 | 1.58E-02 | 4.56E-02 |
| ENSSSCG00000028912 | Uncharacterized protein | 3.02E-02 | 2.72E-02 |
| CFD | Complement factor D | 4.02E-02 | 1.98E-02 |
| DNASE1L1 | deoxyribonuclease I-like 1 | 4.51E-03 | 3.59E-02 |
| ECHDC3 | enoyl CoA hydratase domain containing 3 | 1.21E-03 | 2.04E-02 |
| ENSSSCG00000024587 | Uncharacterized protein | 2.49E-02 | 2.64E-02 |
| ENSSSCG00000028244 | Uncharacterized protein | 2.41E-02 | 4.91E-02 |
| EDNRA | endothelin receptor type A | 4.56E-02 | 2.42E-02 |
| EFEMP2 | EGF containing fibulin-like extracellular matrix protein 2 | 4.86E-02 | 1.66E-02 |
| EHD2 | EH-domain containing 2 | 9.26E-03 | 1.20E-02 |
| ENSSSCG00000011239 | Uncharacterized protein | 3.85E-02 | 9.09E-03 |
| ENSSSCG00000021406 | Uncharacterized protein | 1.35E-02 | 4.85E-02 |
| ENSSSCG00000025934 | Uncharacterized protein | 2.75E-02 | 7.72E-03 |
| ENSSSCG00000029074 | Uncharacterized protein | 1.61E-02 | 3.58E-02 |
| EPHX1 | Sus scrofa epoxide hydrolase 1, microsomal (xenobiotic) (EPHX1) | 1.61E-02 | 1.11E-02 |
| FAH | fumarylacetoacetate hydrolase (fumarylacetoacetase) | 1.66E-02 | 8.16E-03 |
| FAM213A | family with sequence similarity 213, member A | 4.93E-02 | 1.01E-02 |
| FCGRT | Sus scrofa Fc fragment of IgG, receptor, transporter, alpha | 3.42E-02 | 4.56E-02 |
| FDXR | NADPH:adrenodoxin oxidoreductase, mitochondrial | 1.61E-02 | 1.29E-02 |
| FGFR1 | Fibroblast growth factor receptor 1 | 4.69E-02 | 1.21E-02 |
| ENSSSCG00000022236 | Uncharacterized protein | 4.02E-02 | 1.52E-02 |
| ENSSSCG00000002797 | Uncharacterized protein | 4.29E-02 | 2.22E-02 |
| GRK5 | G protein-coupled receptor kinase 5 | 4.60E-02 | 2.87E-03 |
| GSDMD | gasdermin D | 4.11E-02 | 1.36E-02 |
| ENSSSCG00000000620 | Uncharacterized protein | 2.01E-02 | 3.84E-03 |
| ITM2C | Sus scrofa integral membrane protein 2C | 4.71E-02 | 4.75E-02 |
| ENSSSCG00000004207 | Uncharacterized protein | 3.99E-02 | 2.36E-02 |
| LAMB2 | laminin, beta 2 (laminin S) | 1.23E-02 | 2.81E-02 |
| LAMC3 | laminin, gamma 3 | 1.30E-02 | 2.15E-02 |
| LIPA | lipase A, lysosomal acid, cholesterol esterase | 4.50E-02 | 3.84E-02 |
| ENSSSCG00000023235 | Uncharacterized protein | 2.63E-02 | 1.23E-02 |
| MAOB | monoamine oxidase B | 3.62E-02 | 2.50E-02 |
| NEU1 | sialidase 1 (lysosomal sialidase) | 4.11E-02 | 4.56E-02 |
| ENSSSCG00000022516 | Uncharacterized protein | 2.23E-02 | 4.97E-02 |
| PGAM1 | phosphoglycerate mutase 1 (brain) | 1.50E-02 | 1.29E-02 |
| PLCB1 | phospholipase C, beta 1 (phosphoinositide-specific) | 4.06E-02 | 4.75E-02 |
| PRDX2 | peroxiredoxin 2 | 4.02E-02 | 4.69E-02 |
| ENSSSCG00000016522 | Uncharacterized protein | 5.88E-03 | 1.20E-02 |
| SERTAD1 | SERTA domain containing 1 | 3.22E-02 | 4.35E-02 |
| ENSSSCG00000011357 | Uncharacterized protein | 3.87E-02 | 4.11E-02 |
| SLC1A5 | solute carrier family 1 (neutral amino acid transporter), member 5 | 4.99E-02 | 3.91E-02 |
| SLC41A1 | solute carrier family 41 (magnesium transporter), member 1 | 4.29E-02 | 7.39E-03 |
| SLC44A2 | Choline transporter-like protein 2 | 4.02E-02 | 1.12E-02 |
| SLC44A4 | Sus scrofa solute carrier family 44, member 4 (SLC44A4), mRNA | 4.98E-02 | 3.50E-02 |
| TMEM176B | transmembrane protein 176B | 4.40E-02 | 7.46E-03 |
| TNFAIP3 | tumor necrosis factor, alpha-induced protein 3 | 2.64E-02 | 5.56E-03 |
| TPM4 | tropomysin alpha-4 chain | 5.77E-03 | 3.10E-02 |
| VIM | Vimentin | 4.02E-02 | 1.12E-02 |
Genes differentially expressed in both breeds are presented with gene symbol, gene name and significance level (FDR) for Landrace (L) and Duroc (D)
Fig. 1Gene ontology classification of the differentially expressed genes. The figure shows the GO enrichments of the differentially expressed genes in terms of the biological process, cellular component and molecular function classes
Effects of putative SNPs
| SNP effect | After filtration | Joined with gene expression results | ||
|---|---|---|---|---|
| Landrace | Duroc | Landrace | Duroc | |
| 3’UTR | 17,741 | 17,715 | 573 | 627 |
| 5’UTR | 3622 | 3691 | 62 | 102 |
| Frameshift | 453 | 516 | 3 | 12 |
| Missense | 9946 | 10,424 | 267 | 246 |
| Splice acceptor | 16 | 17 | 0 | 0 |
| Splice donor | 12 | 12 | 0 | 0 |
| Splice site region | 338 | 362 | 3 | 7 |
| Start lost | 13 | 8 | 1 | 0 |
| Stop gained | 68 | 63 | 0 | 3 |
| Stop lost | 27 | 34 | 0 | 2 |
| Synonymous | 21,060 | 21,273 | 610 | 731 |
| SNP impact | ||||
| High | 600 | 663 | 4 | 17 |
| Moderate | 10,006 | 10,486 | 269 | 250 |
| Low | 21,974 | 22,200 | 623 | 752 |
| Modifier | 23,251 | 23,293 | 676 | 807 |
SNP effect according to SnpEff for putative polymorphisms detected in Landrace and Duroc. The results presented are after filtration and joined with differentially expressed genes. Some SNPs have more than one predicted effect